Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus.

Vitelli A, Quirion MR, Lo CY, Misplon JA, Grabowska AK, Pierantoni A, Ammendola V, Price GE, Soboleski MR, Cortese R, Colloca S, Nicosia A, Epstein SL.

PLoS One. 2013;8(3):e55435. doi: 10.1371/journal.pone.0055435. Epub 2013 Mar 11.

2.

Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.

Patel A, Gray M, Li Y, Kobasa D, Yao X, Kobinger GP.

Vaccine. 2012 Jan 11;30(3):626-36. doi: 10.1016/j.vaccine.2011.11.017. Epub 2011 Nov 23.

PMID:
22119588
3.

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.

Antrobus RD, Coughlan L, Berthoud TK, Dicks MD, Hill AV, Lambe T, Gilbert SC.

Mol Ther. 2014 Mar;22(3):668-74. doi: 10.1038/mt.2013.284. Epub 2013 Dec 30.

4.
5.

Single-dose vaccination of a recombinant parainfluenza virus 5 expressing NP from H5N1 virus provides broad immunity against influenza A viruses.

Li Z, Gabbard JD, Mooney A, Gao X, Chen Z, Place RJ, Tompkins SM, He B.

J Virol. 2013 May;87(10):5985-93. doi: 10.1128/JVI.00120-13. Epub 2013 Mar 20.

6.

Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1.

Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL.

Emerg Infect Dis. 2007 Mar;13(3):426-35.

7.

Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice.

Huang B, Wang W, Li R, Wang X, Jiang T, Qi X, Gao Y, Tan W, Ruan L.

Virol J. 2012 Dec 29;9:322. doi: 10.1186/1743-422X-9-322.

8.

Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein.

Roy S, Kobinger GP, Lin J, Figueredo J, Calcedo R, Kobasa D, Wilson JM.

Vaccine. 2007 Sep 28;25(39-40):6845-51. Epub 2007 Aug 6.

9.

Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.

Altstein AD, Gitelman AK, Smirnov YA, Piskareva LM, Zakharova LG, Pashvykina GV, Shmarov MM, Zhirnov OP, Varich NP, Ilyinskii PO, Shneider AM.

Arch Virol. 2006 May;151(5):921-31. Epub 2005 Nov 15.

PMID:
16292596
10.

Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses.

Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Houser KV, Tumpey TM, Epstein SL.

Vaccine. 2009 Nov 5;27(47):6512-21. doi: 10.1016/j.vaccine.2009.08.053. Epub 2009 Sep 1.

PMID:
19729082
11.

Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV).

Sipo I, Knauf M, Fechner H, Poller W, Planz O, Kurth R, Norley S.

Vaccine. 2011 Feb 11;29(8):1690-9. doi: 10.1016/j.vaccine.2010.12.037. Epub 2010 Dec 30.

PMID:
21195079
12.

Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.

Luo M, Tao P, Li J, Zhou S, Guo D, Pan Z.

J Virol Methods. 2008 Dec;154(1-2):121-7. doi: 10.1016/j.jviromet.2008.08.011. Epub 2008 Sep 27.

PMID:
18789973
13.

Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.

Wang W, Li R, Deng Y, Lu N, Chen H, Meng X, Wang W, Wang X, Yan K, Qi X, Zhang X, Xin W, Lu Z, Li X, Bian T, Gao Y, Tan W, Ruan L.

Clin Vaccine Immunol. 2015 Jun;22(6):618-30. doi: 10.1128/CVI.00091-15. Epub 2015 Apr 1.

14.

A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.

Eliasson DG, Helgeby A, Schön K, Nygren C, El-Bakkouri K, Fiers W, Saelens X, Lövgren KB, Nyström I, Lycke NY.

Vaccine. 2011 May 23;29(23):3951-61. doi: 10.1016/j.vaccine.2011.03.090. Epub 2011 Apr 8.

PMID:
21481325
15.

[Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].

Stepanova LA, Kovaleva AA, Potapchuk MV, Korotkov AV, Kupriianov VV, Blokhina EA, Kotliarov RIu, Tsybalova LM.

Vopr Virusol. 2013 May-Jun;58(3):21-5. Russian.

PMID:
24006628
16.

Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine.

Pandey A, Singh N, Vemula SV, Couëtil L, Katz JM, Donis R, Sambhara S, Mittal SK.

PLoS One. 2012;7(3):e33428. doi: 10.1371/journal.pone.0033428. Epub 2012 Mar 14.

17.

CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.

Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, Löwenadler B, Fiers W, Saelens X, Lycke N.

Vaccine. 2008 Feb 26;26(9):1243-52. doi: 10.1016/j.vaccine.2007.12.027. Epub 2008 Jan 10.

PMID:
18243429
18.

Progress on adenovirus-vectored universal influenza vaccines.

Xiang K, Ying G, Yan Z, Shanshan Y, Lei Z, Hongjun L, Maosheng S.

Hum Vaccin Immunother. 2015;11(5):1209-22. doi: 10.1080/21645515.2015.1016674. Review.

19.

A Novel Live Pichinde Virus-Based Vaccine Vector Induces Enhanced Humoral and Cellular Immunity after a Booster Dose.

Dhanwani R, Zhou Y, Huang Q, Verma V, Dileepan M, Ly H, Liang Y.

J Virol. 2015 Dec 16;90(5):2551-60. doi: 10.1128/JVI.02705-15.

20.

Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.

Park KS, Seo YB, Lee JY, Im SJ, Seo SH, Song MS, Choi YK, Sung YC.

Vaccine. 2011 Jul 26;29(33):5481-7. doi: 10.1016/j.vaccine.2011.05.062. Epub 2011 Jun 12.

PMID:
21664216
Items per page

Supplemental Content

Write to the Help Desk